title: Drug-eluting stents compared with bare metal stents improve late outcome after saphenous vein graft but not after large native vessel interventions.
abstract: OBJECTIVE
  To define long-term efficacy of different stent types in saphenous vein graft (SVG) interventions.
  
  
  METHODS
  In BASKET (Basel Stent Cost Effectiveness Trial), major adverse cardiac events (MACE), i.e. cardiac death, myocardial infarction and symptom-driven target vessel revascularization (TVR) were assessed after 18 months comparing drug-eluting stents (DES) versus bare metal stents (BMS), and SVG and large native vessels (> or =3.0 mm).
  
  
  RESULTS
  Large vessel interventions were performed in 605 patients. Patients with SVG interventions (n = 47, 8%) were older and had more often hypertension, prior myocardial infarction, prior revascularization and multivessel disease and less frequent ST-elevation myocardial infarction than patients with large native vessel interventions (n = 558, 92%). Stent number and length were higher in SVG than in large native vessel interventions. Baseline characteristics were similar for DES and BMS. In SVG stenting, long-term outcome was better in DES- than in BMS-treated patients (MACE 21 vs. 62%, p = 0.007, mainly due to TVR 18 vs. 46%, p = 0.045), but for large native vessel stenting, no significant difference was noted (MACE: 13 vs. 16%, p = 0.40).
  
  
  CONCLUSIONS
  Among patients with SVG disease, treatment with DES resulted in a better long-term outcome than treatment with BMS. In contrast, no DES benefit was found in similarly sized native vessels regarding MACE.
authors.affiliation: Department of Cardiology, University Hospital Basel, Basel, Switzerland.
authors.forename: Raban V
authors.initials: RV
authors.lastname: Jeger
authors.forename: Stefan
authors.initials: S
authors.lastname: Schneiter
authors.forename: Christoph
authors.initials: C
authors.lastname: Kaiser
authors.forename: Piero O
authors.initials: PO
authors.lastname: Bonetti
authors.forename: Hanspeter
authors.initials: H
authors.lastname: Brunner-La Rocca
authors.forename: Michael
authors.initials: M
authors.lastname: Handke
authors.forename: Stefan
authors.initials: S
authors.lastname: Osswald
authors.forename: Peter T
authors.initials: PT
authors.lastname: Buser
authors.forename: Matthias E
authors.initials: ME
authors.lastname: Pfisterer
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D017130:Angioplasty; D001026:Coronary Artery Bypass / Q000401:mortality*; D003327:Coronary Disease / Q000401:mortality* / Q000601:surgery*; D023903:Coronary Restenosis / Q000401:mortality / Q000628:therapy*; D054855:Drug-Eluting Stents / Q000706:statistics & numerical data*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008670:Metals; D008875:Middle Aged; D012189:Retrospective Studies; D012501:Saphenous Vein / Q000637:transplantation*; D016896:Treatment Outcome
chemical_list: D008670:Metals